The success of clinical trials of selective B‐cell depletion in patients with relapsing multiple
sclerosis (MS) and primary progressive MS has led to a conceptual shift in the …

Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Importance Accumulation of disability in multiple sclerosis may occur as relapse-associated
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …

These updated EBMT guidelines review the clinical evidence, registry activity and
mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple …

Objective To evaluate the clinical consequences of extended interval dosing (EID) of
ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease …

A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after
starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

Background: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple
sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance …

Two different treatment paradigms are most often used in multiple sclerosis (MS). An
escalation or induction approach is considered when treating a patient early in the disease …

Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …